International Journal of Advanced Research in Medicine
2022, Vol. 4, Issue 1, Part C
A comparative study on the efficacy of Dexmedetomidine and tramadol on post-spinal anaesthesia shivering
Author(s): Leelavathi Bikumalla
Abstract:Background of this study: Shivering is the most general adverse effect occurs after the administration of anaesthesia with several aetiologies. In order to control the shivering, drug such as tramadol is broadly required. Nausea as well as vomiting is majorly caused by the drug tramadol. Therefore, there is a search for the efficient drug that lacking of adverse effects.
Aim of the study: The goal of this study was to evaluate the efficiency of tramadol as well as dexmedetomidine in the medication of post spinal anesthesia shivering and also to examine their associated adverse effects.
Materials and Methods: 60 number of patients having shivering after the administration of spinal anaesthesia were arbitrarily separated to two groups include Group D and Group T, each injected with 0.5 µg/kg of dexmedetomidine and 0.5 m/g/kg of tramadol along with 100 ml of normal saline respectively. The rate of response, onset of shivering, time taken for cessation of shivering, percentage of recurrence as well as associated effects was observed. All the data were assessed by means of independent t test analysis as well as chi square assessment to find out the significant value.
Results: Both the drugs such as tramadol and dexmedetomidine are efficiently managed the shivering effectively as well as both take approximately the similar time for its deactivation. This study found that the associated unfavourable effects include vomiting and nausea is higher in Group T, so the patients in Group T need proper medication. The occurrence of recurrence of shivering was elevated in Group T.
Conclusion: Dexmedetomidine provides good outcomes as compared to tramadol with less associated effects.
Leelavathi Bikumalla. A comparative study on the efficacy of Dexmedetomidine and tramadol on post-spinal anaesthesia shivering. Int J Adv Res Med 2022;4(1):186-189. DOI: 10.22271/27069567.2022.v4.i1c.371